Učitavanje...
Managing breast cancers with low estrogen receptor and HER2 by drugging both: Commentary on manuscript # CCR-13-1260R “Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in Postmenopausal Women With Hormone Receptor-Positive, HER-2 Negative Metastatic Breast Cancer”
Low ER levels in breast tumors are associated with poorer response to anti-estrogen therapy. Finn et al. identified low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor Lapatinib to an anti-estrogen treatment regimen in patients with metastatic breast can...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3946528/ https://ncbi.nlm.nih.gov/pubmed/24352641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2994 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|